Wilson Aarhus

2026

Preliminary Program

EASL Endorsed

Wilson Aarhus

Thursday April 30

19.00-22.00	Welcome dinner at the venue Comwell, Værkmestergade 2, DK-8000 Aarhus C	

Friday May 1
Morning

9.00	Welcome	*President, Thomas Sandahl (Aarhus)*

Session I: Welcome session
Chairs: Thomas Sandahl, Svetlana Lutsenko

9.10	WDGA – Wilson Disease Global Alliance	*Lisbet Ottesen (Copenhagen)*
9.30	Gut-liver-brain Interactions	*Valentina Medici (Sacramento)*
9.50	The Brain and Copper: Beyond Wilson Disease	*Aurélia Poujois (Paris)*
10.10	ABS 1	*TBA*
10.25	Coffee break	

Session II: Neurology I
Chairs: Aurélia Poujois, Petr Dusek

11.00	Modified UWDRS	*Petr Dusek (Prague)*
11.20	The added value of Neurophysiology in WD with movement disorder	*Mickaël Alexandre Obadia (Paris)*
11.35	Is r-TMS the future treatment for dysarthria in WD	*Michaela Pernon (Paris)*
11.50	ABS 2	*TBA*
12.05	ABS 3	*TBA*
12.20	ABS 4	*TBA*
12.35	Lunch	

Friday May 1
Afternoon

Session III: Epidemiology
Chairs: Tomasz Litwin, Karl Heinz Weiss

13.30	Has presenting phenotype and its relation to gender changed over the years?	*Karina Rewitz (Aarhus)*
13.45	Genotype-Phenotype Correlation and Precision Pharmacotherapy in Wilson Disease	*Zhi-Ying Wu (Hangzhou)*
14.00	Wilson disease in Brazil	*Marta Mitiko Deguti (Sao Paulo)*
14.15	ABS 5	*TBA*
14.30	ABS 6	*TBA*

Session IV: Poster session

14.45	Poster viewing and coffee break	

Session V: ALF in WD
Chairs: Seema Alam, Marina Berenguer, Tudor Pop

16.00	ALF in Wilson disease	*Anil Dhawan (London)*
16.20	NCC in the diagnosis of ALF	*Eduardo Couchonnal (Lyon)*
16.40	Liver failure in Wilson disease in India	*Seema Alam (New Delhi)*
16.55	ABS 7	*TBA*
17.10	ABS 8	*TBA*
17.25	End of day	
19.00	Dinner at Martin IB, TRÆ, Kalkværksvej 5, Sydhavnen, DK-8000 Aarhus C	

Saturday May 2
Morning

Session VI: Basic science
Chairs: Hans Zischka, Roman Polishchuk

9.00	Functional Screen of Wilson Variants	*Svetlana Lutsenko (Baltimore)*
9.20	Trace Copper causes severe Iron Toxicity targeting mitochondrial Iron-Sulfur cluster enzymes	*Judith Sailer (Munich)*
9.35	ABS 9	*TBA*
9.50	Prion protein promotes copper toxicity in Wilson disease	*Roman Polishchuk (Pozzuoli)*
10.10	The importance of mitochondria in rescuing copper induced liver failure	*Hans Zischka (Munich)*
10.30	Coffee break	

Session VII: Screening for WD and disorders of copper metabolism
Chairs: Aftab Ala, Anil Dhawan

11.00	Current screening programs using ATP7B peptides	*Sihoun Hahn (Seattle)*
11.20	The parents' perspective	*Rhonda Rowland (New York)*
11.40	DNA-based newborn screening for disorders of copper metabolism	*Stephen Kaler (New York)*
11.55	Debate: The baby has a positive test, now what?	*Piotr Socha (Warsaw) /Rima Fawaz (New Haven)*
12.20	ABS 10	*TBA*
12.35	Lunch	

Saturday May 2
Afternoon

Session VIII: Bioavailable copper measurements and liver biochemistries - use for monitoring and diagnosis
Chairs: Aurélia Poujois, Anna Czlonkowska

13.30	ANCC and CuExc	*Chris Harrington (Guildford)*
13.50	Characterization of Labile Bound Copper by a Dual Filtration Method	*Joshua Bornhorst (Rochester)*
14.05	Exchangeable copper and REC in 2026	*Nouzha Djebrani-Oussedik (Paris)*
14.25	Liver biochemistry as surrogate marker in WD	*Marina Berenguer (Valencia)*
14.40	Incorporating meaningful endpoints for treatment of WD into practice - role of NIT	*Michael Schilsky (New Haven)*
15.00	Coffee break	

Session IX: The diagnosis
Chairs: Peter Ott, Michael Schilsky

15.30	Introduction	*Peter Ott (Aarhus)*
15.40	The value of genetic analysis	*Luis García Villarreal (Gran Canaria)*
16.00	Wilson Disease – a single gene disorder?	*Dorte Lildballe (Aarhus)*
16.15	The biopsy, total copper and metallothioneines	*Zoe Mariño (Barcelona)*
16.35	Leipzig after 2 decades of service	*Karl Heinz Weiss (Heidelberg)*
16.55	Panel discussion	
17.25	End of day	
19.00	Dinner at Havnær, Dagmar Petersens Gade 119, DK-8000 Aarhus C	

Sunday May 3
Morning

Session X: Pharmacotherapeutic advances for WD
Chairs: Zoe Mariño, Albert Stättermayer

9.00	Unmet needs in the pharmacological treatment of Wilson disease	*Aftab Ala (London)*
9.15	TDMQ20, a potential new drug for WD	*Bernard Meunier (Toulouse)*
9.30	TTM: Lost battle or a rising Phoenix?	*Fred Askari (Ann Arbor)*
9.45	ABS 11	*TBA*
10.00	^{64}Cu PET update	*Thomas Sandahl (Aarhus)*
10.20	Coffee break	

Session XI: Curing WD - gene therapy and ATP7B gene repair
Chairs: Fred Askari, Tom Warner

11.00	Interim results of the ongoing Ultragenyx Phase 1-3 clinical trial of AAV9 gene therapy for Wilson Disease	*Andrew Grimm* (*Ultragenyx)*
11.20	Does liver fibrosis affect AAV treatment?	*Pasquale Piccolo (Pozzuoli)*
11.40	Genetic modification of ATP7B gene in human cells using RNA-based CRISPR/Cas9 technology	*Vanessa Sandfort (Münster)*
12.00	Prime editing and gene repair in WD	*TBA* (*Prime Medicine)*
12.15	ABS 12	*TBA*
12.30	Conference summary and take home messages	*Michael Schilsky (New Haven)*
12.45	Closing remarks	*Thomas Sandahl (Aarhus)*
12.50	Lunch	
13.50	Departure	

Wilson Aarhus

Wilson Aarhus

Wilson Aarhus

Wilson Aarhus